

# Matthias Gehringer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7258895/matthias-gehringer-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

731  
citations

14  
h-index

27  
g-index

41  
ext. papers

982  
ext. citations

5.6  
avg, IF

5.04  
L-index

#	Paper	IF	Citations
31	Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 5673-5724	8.3	218
30	Inhibitors of c-Jun N-terminal kinases: an update. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 72-95	8.3	63
29	Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. <i>Cell Chemical Biology</i> , <b>2016</b> , 23, 1335-1340	8.2	62
28	The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. <i>ACS Chemical Biology</i> , <b>2017</b> , 12, 1297-1307	4.9	52
27	Silica-supported L-proline organocatalysts for asymmetric aldolisation. <i>Tetrahedron: Asymmetry</i> , <b>2009</b> , 20, 2880-2885		44
26	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). <i>Expert Opinion on Therapeutic Patents</i> , <b>2015</b> , 25, 849-72	6.8	39
25	Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes. <i>ChemMedChem</i> , <b>2014</b> , 9, 277-81	3.7	29
24	Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 5350-5366	8.3	27
23	Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. <i>ChemMedChem</i> , <b>2014</b> , 9, 2516-27	3.7	25
22	Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2017</b> , 27, 4229-4237	2.9	23
21	The chemistry and biology of mycolactones. <i>Beilstein Journal of Organic Chemistry</i> , <b>2017</b> , 13, 1596-1660	2.5	23
20	Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. <i>Angewandte Chemie - International Edition</i> , <b>2017</b> , 56, 15504-15505	16.4	22
19	Developing Small-Molecule Inhibitors of HECT-Type Ubiquitin Ligases for Therapeutic Applications: Challenges and Opportunities. <i>ChemBioChem</i> , <b>2018</b> , 19, 2123-2135	3.8	21
18	Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. <i>ACS Combinatorial Science</i> , <b>2015</b> , 17, 5-10	3.9	14
17	A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors. <i>Analytical Methods</i> , <b>2014</b> , 6, 8817-8822	3.2	11
16	New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential. <i>Amino Acids</i> , <b>2015</b> , 47, 1155-66	3.5	9
15	Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6

14	Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). <i>Future Medicinal Chemistry</i> , <b>2016</b> , 8, 1537-51	4.1	6
13	Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of <i>Mycobacterium ulcerans</i> . <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008357	4.8	5
12	Configurationaly Stabilized Analogs of Exotoxins Mycolactones A and B Reveal the Importance of Side Chain Geometry for Mycolactone Virulence. <i>Organic Letters</i> , <b>2019</b> , 21, 5853-5857	6.2	5
11	Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. <i>Inflammopharmacology</i> , <b>2021</b> , 29, 595-615	5.1	5
10	Covalent Kinase Inhibitors: An Overview. <i>Topics in Medicinal Chemistry</i> , <b>2020</b> , 43-94	0.4	3
9	Nocathioamides, Uncovered by a Tunable Metabologenomic Approach, Define a Novel Class of Chimeric Lanthipeptides. <i>Angewandte Chemie - International Edition</i> , <b>2021</b> , 60, 16472-16479	16.4	2
8	Covalent Janus Kinase 3 Inhibitors. <i>Topics in Medicinal Chemistry</i> , <b>2020</b> , 225-256	0.4	1
7	An Antigen Capture Assay for the Detection of Mycolactone, the Polyketide Toxin of. <i>Journal of Immunology</i> , <b>2021</b> , 206, 2753-2762	5.3	1
6	Chemical Probes for Understudied Kinases: Challenges and Opportunities. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> ,	8.3	1
5	N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine. <i>MolBank</i> , <b>2021</b> , 2021, M1181	0.5	0
4	Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.. <i>Journal of Medicinal Chemistry</i> , <b>2022</b> , 65, 4616-4632	8.3	0
3	Metabolism of a novel skepinone L-like p38 mitogen-activated protein kinase inhibitor. <i>MedChemComm</i> , <b>2014</b> , 5, 808	5	
2	2-(3-((3R,4R)-4-Methyl-3-[meth-yl(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl)oxetan-3-yl)aceto-nitrile monohydrate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , <b>2014</b> , 70, o382-3		
1	tert-Butyl N-[(3R,4R)-1-(2-cyano-acet-yl)-4-methyl-piperidin-3-yl]-N-methyl-carbamate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , <b>2013</b> , 69, o935		